A Phase 3, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp

Trial Profile

A Phase 3, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp

Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Apremilast (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Acronyms STYLE
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 28 Sep 2017 Planned End Date changed from 19 Feb 2020 to 19 Mar 2019.
    • 28 Sep 2017 Planned primary completion date changed from 19 Feb 2019 to 18 Oct 2018.
    • 12 Jul 2017 Planned End Date changed from 15 Jan 2020 to 19 Feb 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top